Equity Overview
Price & Market Data
Price: $44.25
Daily Change: +$1.09 / 2.46%
Daily Range: $44.25 - $44.25
Market Cap: $2,580,985,600
Daily Volume: 2,064
Performance Metrics
1 Week: 17.96%
1 Month: 46.60%
3 Months: 183.8%
6 Months: 120.1%
1 Year: 141.5%
YTD: 180.3%
Company Details
Employees: 60
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.